GlassScriptPhysician profile
Erik D Wert
NPI 1881692739
$3,774.92
in general payments reported to CMS, 2019-2025
30 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.65 · 2020: $329 · 2021: $409 · 2022: $609 · 2023: $445 · 2024: $919 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,782.72 | 2020-2025 | Biktarvy, Ambisome, Veklury |
| Viiv Healthcare Company | $757.91 | 2021-2025 | Apretude, Cabenuva, Dovato |
| Glaxosmithkline, LLC. | $156.09 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $143.73 | 2022-2025 | Vraylar, Qulipta |
| Pfizer INC. | $136.15 | 2023-2025 | |
| Amgen INC. | $103.87 | 2020-2025 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $79.25 | 2021-2025 | Wegovy, Ozempic |
| Axsome Therapeutics, INC. | $75.03 | 2024-2025 | Auvelity, Sunosi |
| Merck Sharp & Dohme LLC | $68.19 | 2020-2024 | Gardasil 9, Capvaxive, Gardasil |
| Paratek Pharmaceuticals, INC. | $51.19 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $49.23 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $48.44 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $44.63 | 2020-2024 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $22.33 | 2024 | Rexulti |
| Dexcom, INC. | $21.59 | 2024 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $21.14 | 2020 | |
| Seqirus USA INC | $19.86 | 2025 | Flucelvax |
| Antares Pharma, INC. | $18.25 | 2025 | Xyosted |
| Biohaven Pharmaceutical Holding Company LTD. | $17.31 | 2022 | |
| Abiomed | $16.97 | 2025 | |
| Lilly USA, LLC | $16.43 | 2024 | Zepbound, Jardiance |
| Dynavax Technologies Corporation | $15.79 | 2024 | Heplisav-B |
| Amarin Pharma, INC. | $15.65 | 2020 | |
| Esperion Therapeutics, INC. | $15.51 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.37 | 2025 | |
| Nestle Healthcare Nutrition INC. | $13.88 | 2022 | |
| Clarus Therapeutics INC. | $13.27 | 2021 | |
| Allergan, INC. | $11.93 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.84 | 2020 | |
| Eisai INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Wert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.